Full Text View
Tabular View
Study Results
Related Studies
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
This study has been completed.
First Received: March 26, 2004   Last Updated: November 16, 2009   History of Changes
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00080301
  Purpose

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.


Condition Intervention Phase
Breast Cancer
Metastases
 Drug: Ixabepilone + Capecitabine
Drug: Capecitabine
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
Drug Information available for: Capecitabine Ixabepilone
U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) [ Time Frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall Response Rate (ORR) Per IRRC [ Time Frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity ] [ Designated as safety issue: No ]
  • Duration of Response Per IRRC [ Time Frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity ] [ Designated as safety issue: No ]
  • Time to Response Per IRRC [ Time Frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity ] [ Designated as safety issue: No ]
  • Overall Survival (OS) [ Time Frame: from date of randomization until death ] [ Designated as safety issue: No ]
  • Treatment-related Safety Summary [ Time Frame: safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible. ] [ Designated as safety issue: Yes ]
  • Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI) [ Time Frame: Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment. ] [ Designated as safety issue: No ]

Enrollment: 752
Study Start Date: September 2003
Study Completion Date: March 2008
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A: Experimental Drug: Ixabepilone + Capecitabine

Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity

Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
B: Active Comparator Drug: Capecitabine
Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria
  • Patients must have received either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy.
  • Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).
  • Patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline.
  • Patients must be resistant to taxane therapy.
  • Patients may not have any history of brain and/or leptomeningeal metastases.
  • Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory).
  • Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00080301

  Hide Study Locations
Locations
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
Vallejo, California, United States
Local Institution
San Francisco, California, United States
United States, Colorado
Local Institution
Denver, Colorado, United States
United States, Connecticut
Local Institution
Hartford, Connecticut, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
Orlando, Florida, United States
United States, Maryland
Local Institution
Baltimore, Maryland, United States
United States, Massachusetts
Local Institution
Burlington, Massachusetts, United States
United States, Mississippi
Local Institution
Jackson, Mississippi, United States
United States, Missouri
Local Institution
Kansas City, Missouri, United States
Local Institution
Columbia, Missouri, United States
Local Institution
Saint Louis, Missouri, United States
United States, Nebraska
Local Institution
Omaha, Nebraska, United States
United States, New Jersey
Local Institution
Livingston, New Jersey, United States
Local Institution
New Brunswick, New Jersey, United States
United States, New Mexico
Local Institution
Albuquerque, New Mexico, United States
United States, New York
Local Institution
New York, New York, United States
United States, Ohio
Local Institution
Columbus, Ohio, United States
United States, Oklahoma
Local Institution
Tulsa, Oklahoma, United States
Local Institution
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Local Institution
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Local Institution
Greenville, South Carolina, United States
Local Institution
Columbia, South Carolina, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
Local Institution
Knoxville, Tennessee, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Houston, Texas, United States
United States, Utah
Local Institution
Ogden, Utah, United States
United States, Vermont
Local Institution
Burlington, Vermont, United States
United States, Washington
Local Institution
Tacoma, Washington, United States
United States, West Virginia
Local Institution
Morgantown, West Virginia, United States
Argentina
Local Institution
Cordoba, Argentina
Local Institution
Neuquen, Argentina
Local Institution
Santa Fe, Argentina
Argentina, Buenos Aires
Local Institution
Pilar, Buenos Aires, Argentina
Local Institution
La Plata, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Haedo, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Quilmes, Buenos Aires, Argentina
Local Institution
Mar Del Plata, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Argentina, BuenosAires
Local Institution
Lanus, BuenosAires, Argentina
Argentina, Santa Fe
Local Institution
Rosario, Santa Fe, Argentina
Belgium
Local Institution
Leuven, Belgium
Local Institution
Liege, Belgium
Local Institution
Edegem, Belgium
Local Institution
Liege, Belgium
Local Institution
Gent, Belgium
Brazil
Local Institution
Sao Paulo, Brazil
Local Institution
Sao Paulo, Brazil
Brazil, Ceara
Local Institution
Fortaleza, Ceara, Brazil
Brazil, Mina Gerais
Local Institution
Belo Horizonte, Mina Gerais, Brazil
Brazil, Parana
Local Institution
Curitiba, Parana, Brazil
Brazil, Rio Grande Do Sul
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil
Brazil, Sao Paulo
Local Institution
Sao Paulo - Sp, Sao Paulo, Brazil
Local Institution
Santo Andre, Sao Paulo, Brazil
Local Institution
Jau, Sao Paulo, Brazil
Canada, British Columbia
Local Institution
Vancouver, British Columbia, Canada
Canada, Ontario
Local Institution
Toronto, Ontario, Canada
Local Institution
Oshawa, Ontario, Canada
Canada, Quebec
Local Institution
Montreal, Quebec, Canada
China
Local Institution
Shanghai, China
Local Institution
Beijing, China
Local Institution
Beijing, China
Local Institution
Beijing, China
China, Guangdong
Local Institution
Guangzhou, Guangdong, China
China, Jiangsu
Local Institution
Nanjing, Jiangsu, China
Local Institution
Nanjing, Jiangsu, China
China, Shan3xi
Local Institution
Xi'An, Shan3xi, China
China, Shandong
Local Institution
Jinan, Shandong, China
China, Shanghai
Local Institution
Beijing, Shanghai, China
France
Local Institution
Besancon, France
Local Institution
Toulouse Cedex 3, France
Local Institution
Angers, France
Local Institution
Clermont-Ferrand, France
Local Institution
Saint-Cloud Cedex, France
Local Institution
St. Herblain Cedex, France
Local Institution
Avignon Cedex 2, France
Local Institution
Bobigny, France
Local Institution
Bordeaux, France
Local Institution
Saint Brieuc Cedex, France
Local Institution
Strasbourg Cedex, France
Local Institution
Nice, France
Local Institution
Lyon, France
Local Institution
Nantes, France
Local Institution
Bayonne, France
Germany
Local Institution
Erlangen, Germany
Local Institution
Berlin, Germany
Local Institution
Duisburg, Germany
Greece
Local Institution
Athens, Greece
Local Institution
Thessaloniki, Greece
Local Institution
Athens, Greece
Hungary
Local Institution
Budapest, Hungary
Local Institution
Debrecen, Hungary
Local Institution
Budapest, Hungary
Local Institution
Gyor, Hungary
Local Institution
Pecs, Hungary
Local Institution
Budapest, Hungary
Italy
Local Institution
Candiolo (To), Italy
Local Institution
Brescia, Italy
Local Institution
Forli, Italy
Local Institution
San Giovanni Rotondo, Italy
Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Local Institution
Incheon, Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Malaysia
Local Institution
Kuala Lumpur, Malaysia
Malaysia, Negeri Sembilan
Local Institution
Nilai, Negeri Sembilan, Malaysia
Mexico
Local Institution
Chihuahua, Mexico
Local Institution
San Luis Potosi, Mexico
Local Institution
Distrito Federal, Mexico
Mexico, Guerrero
Local Institution
Acapulco, Guerrero, Mexico
Mexico, Yucatan
Local Institution
Merida, Yucatan, Mexico
Peru
Local Institution
Lima, Peru
Local Institution
Lima, Peru
Philippines
Local Institution
Quezon, Philippines
Local Institution
Quezon City, Philippines
Local Institution
Manila, Philippines
Poland
Local Institution
Gdansk, Poland
Local Institution
Opole, Poland
Spain
Local Institution
Barcelona, Spain
Local Institution
Madrid, Spain
Local Institution
Valencia, Spain
Local Institution
Barcelona, Spain
Local Institution
Barcelona, Spain
Local Institution
Girona, Spain
Local Institution
Zaragoza, Spain
Sweden
Local Institution
Stockholm, Sweden
Local Institution
Gothenburg, Sweden
Taiwan
Local Institution
Tainan, Taiwan
Local Institution
Taipei, Taiwan
Thailand
Local Institution
Bangkok, Thailand
Local Institution
Bangkok, Thailand
Local Institution
Bangkok, Thailand
Local Institution
Bangkok, Thailand
United Kingdom, Avon
Local Institution
Bristol, Avon, United Kingdom
United Kingdom, Essex
Local Institution
Chelmsford, Essex, United Kingdom
United Kingdom, Greater London
Local Institution
London, Greater London, United Kingdom
Local Institution
London, Greater London, United Kingdom
United Kingdom, Greater Manchester
Local Institution
Manchester, Greater Manchester, United Kingdom
United Kingdom, South Yorkshire
Local Institution
Sheffield, South Yorkshire, United Kingdom
United Kingdom, Surrey
Local Institution
Guildford, Surrey, United Kingdom
United Kingdom, Tyne and Wear
Local Institution
Newcastle-Upon-Tyne, Tyne and Wear, United Kingdom
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
BMS Clinical Trials Disclosure  This link exits the ClinicalTrials.gov site
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site
Phrma website - CSR synopsis  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Bristol-Myers Squibb ( Study Director )
Study ID Numbers: CA163-046
Study First Received: March 26, 2004
Results First Received: May 1, 2009
Last Updated: November 16, 2009
ClinicalTrials.gov Identifier: NCT00080301     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
Metastatic Breast Cancer

Additional relevant MeSH terms:
Antimetabolites
Capecitabine
Antimetabolites, Antineoplastic
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Skin Diseases
Antineoplastic Agents
Epothilones
Mitosis Modulators
Physiological Effects of Drugs
Breast Neoplasms
Antimitotic Agents
 Immunosuppressive Agents
Pharmacologic Actions
Neoplasms
Neoplastic Processes
Neoplasms by Site
Pathologic Processes
Therapeutic Uses
Fluorouracil
Tubulin Modulators
Neoplasm Metastasis
Breast Diseases

ClinicalTrials.gov processed this record on November 27, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services